(19)
(11) EP 2 209 898 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.03.2012 Bulletin 2012/12

(45) Mention of the grant of the patent:
04.01.2012 Bulletin 2012/01

(21) Application number: 08806243.5

(22) Date of filing: 12.09.2008
(51) International Patent Classification (IPC): 
C12N 15/90(2006.01)
C12N 9/02(2006.01)
A01K 67/027(2006.01)
(86) International application number:
PCT/GB2008/003084
(87) International publication number:
WO 2009/034328 (19.03.2009 Gazette 2009/12)

(54)

TWO STEP CLUSTER DELETION AND HUMANISATION

CLUSTER-DELETION UND HUMANISIERUNG IN ZWEI SCHRITTEN

DÉLÉTION EN DEUX ÉTAPES D'UN GROUPE DE GÈNES ET HUMANISATION


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 14.09.2007 GB 0718029

(43) Date of publication of application:
28.07.2010 Bulletin 2010/30

(73) Proprietor: ITI Scotland Limited
Glasgow G2 6HQ (GB)

(72) Inventor:
  • SCHEER, Nico
    50999 Köln (DE)

(74) Representative: Goodfellow, Hugh Robin 
Carpmaels & Ransford One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
EP-A- 1 206 906
WO-A-2006/064197
WO-A-2005/019463
WO-A-2008/081197
   
  • WALLACE HELEN A C ET AL: "Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence" CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 128, no. 1, 11 January 2007 (2007-01-11), pages 197-209, XP002481713 ISSN: 0092-8674 cited in the application
  • WOLF C ROLAND ET AL: "The application of transgenic and humanised nuclear receptor models in drug development" DRUG METABOLISM REVIEWS; 9TH EUROPEAN MEETING OF THE INTERNATIONAL-SOCIETY-FOR-THE-STUDY-OF-XEN OBIOTICS (ISSX), MARCEL DEKKER, NEW YORK, NY, US; MANCHESTER, UK, vol. 38, no. Suppl. 1, 1 January 2006 (2006-01-01), pages 7-8, XP008095774 ISSN: 0360-2532
  • AL-HASANI KEITH ET AL: "Complementation of alpha-thalassaemia in alpha-globin knockout mice with a 191 kb transgene containing the human alpha-globin locus" TRANSGENIC RESEARCH, LONDON, GB, vol. 13, no. 3, 1 June 2004 (2004-06-01), pages 235-243, XP002481712 ISSN: 0962-8819
  • BRAULT V, BESSON V, MAGNOL L, DUCHON A, HÉRAULT Y.: "Cre/loxP-mediated chromosome engineering of the mouse genome." HANDB EXP PHARMACOL., no. 178, 2007, pages 29-48, XP002516469
  • ANDRÉ OUMARD ET AL: "Recommended Method for Chromosome Exploitation: RMCE-based Cassette-exchange Systems in Animal Cell Biotechnology" CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 50, no. 1-3, 14 June 2006 (2006-06-14), pages 93-108, XP019393904 ISSN: 1573-0778
  • VAN HERWAARDEN AE ET AL.: "Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism" J CLIN INVEST., vol. 117, no. 11, 1 November 2007 (2007-11-01), pages 3583-3592, XP002515970
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).